Table 5 Baseline characteristics and studied parameters of the four groups along with statistical comparison
Group A N = 76 | Group B N = 445 | Group C N = 132 | Group D N = 165 | p-value* | |
|---|---|---|---|---|---|
Age (mean ± SD, median, q25-q75, N) | 32.96 ± 4.26, 32.5, 30–36, N = 76 | 33.54 ± 4.59, 34, 31–36, N = 445 | 37.17 ± 5.1, 37, 34–41, N = 132 | 32.48 ± 4.43, 32, 32–35, N = 165 | <.0001 |
BMI (mean, SD) | 24.98 ± 4.29, 23.88, 21.85–27.48, N = 76 | 24.38 ± 3.91, 23.51, 21.87–25.95, N = 445 | 24.69 ± 3.75, 24.16, 21.84–26.81, N = 130 | 24.44 ± 4.32, 23.51, 23.51–25.86, N = 165 | 0.2607 |
No. of foetuses at the observed gestation (N. %) | |||||
1 | 73, 96.05% | 434, 97.53% | 102, 77.27% | 158, 95.76% | <.0001 |
≥ 2 | 3, 3.95% | 11, 2.47% | 30, 22.73% | 7, 4.24% | |
Mean Duration of LMWH (months) | 8.67 ± 1.7, 9, 9–9.5, N = 74 | 8.73 ± 1.32, 9, 9–9.5, N = 445 | 8.69 ± 1.7, 9, 9–9.5, N = 131 | 8.31 ± 1.61, 9, 9–9, N = 162 | <.0001 |
ASA Duration | 6.73 ± 2.76, 8, 6–9, N = 11 | 6.1 ± 2.38, 7, 3–8, N = 79 | 5.46 ± 2.79, 7, 3–8, N = 39 | 7.89 ± 1.97, 8, 8–9, N = 19 | 0.0068 |
Fixed Prophylactic Dose | 26, 34.21% | 262, 58.88% | 66, 50% | 86, 52.12% | <.0001 |
Weight Adjusted prophylactic dose | 16, 21.05% | 144, 32.36% | 51, 38.64% | 61, 36.97% | |
Therapeutic dose of LMWH | 34, 44.74% | 39, 8.76% | 15, 11.36% | 18, 10.91% | |
Concomitant Use of ASA (N, % women rceived ASA within the group) | 11, 14.47% | 81, 18.2% | 40, 30.3% | 20, 12.12% | 0.0006 |
Caesarian | 61, 80.26% | 354, 79.73% | 121, 91.67% | 108, 65.45% | <.0001 |
Live Birth | 74, 97.37% | 441, 99.1% | 128, 96.97% | 164, 99.39% | 0.1632 |
High risk Thrombophilia (positive cases) | 19, 25% | 45, 10.11% | 13, 9.85% | 17, 10.3% | 0.0018 |
APA status (total successful tests N = 363) (positive cases, % within group)) | 16, 29.63% | 57, 29.08% | 16, 27.12% | 11, 20.37% | 0.6264 |